Info on the NovaLung company and their lung products

Info on the NovaLung company and their lung products

Novalung GmbH locations

Highly qualified precision production processes in medtech manufacturing

Downloads

Solutions for Lung Failure

 Novalung‘s mission is to create new solutions for the treatment of lung failure with innovative artificial lungs that “breathe” outside the patient’s body. The pioneering task is to work with leading clinicians around the world to develop new therapies to replace damaging invasive mechanical ventilation.

Novalung GmbH was founded in Hechingen (Baden-Württemberg, Germany) in 2003 through the fusion of leading German and American technologies in the field of artificial lungs and is now active throughout the world. From the outset Novalung has focused on high-quality development and production “Made in Germany“.  Cutting-edge technologies are employed in Novalung’s medtech production facility in the manufacture in particular of the iLA Membrane Ventilator® and NovaPort® vascular access cannulas, both of which have been used to help treat thousands of patients.

click to the NovaLung web site on lungs

A artificial lung in humans ??

First experience with a paracorporeal artificial lung in humans.

Camboni D, Philipp A, Arlt M, Pfeiffer M, Hilker M, Schmid C.

Source

Departments of Cardiothoracic Surgery, University Hospital Regensburg, Germany. dcamboni@arcor.de

Abstract

Lung transplantation is the only treatment option for patients suffering form end-stage respiratory failure. To date, no mechanical device is available to support patients on the waiting list up to months. Here, we summarize our experience with our first two patients, who were supported with a paracorporeal artificial lung (PAL) placed in parallel to the pulmonary circulation with connection to the pulmonary artery and to the left atrium. A low resistance membrane oxygenator (iLA, Novalung, Hirrlingen, Germany) was attached in both patients. Our first patient suffering from a pulmonary veno-occlusive disease was supported for 18 days until he died due to severe sepsis. Our second patient with a primary pulmonary hypertension of unknown origin was supported 62 days followed by successful lung transplantation.
 In conclusion, the experience obtained with these first two patients under PAL encourages further studies and introduction of this promising concept into clinical practice.

PMID: 19282751 [PubMed - indexed

click to see lung more info at ncbi nlm.nih.gov

U.S. COPD Coalition's Semi-Annual Business Meeting

Artificial Lung amrket expands due to innovations

Innovation Expands Artificial Lung Market

Medtech Insight -- Advances in extracorporeal lung support devices are expanding the market for artificial lungs and are helping to extend and save the lives of patients with acute and chronic pulmonary disease.

 At the Society of Thoracic Surgeons' annual meeting held in San Diego in January, researchers discussed new low-flow percutaneous catheters, advances in low-resistance membrane oxygenators, and improvements in pump designs that are enabling simpler, less invasive, and more portable solutions for treating patients with respiratory failure.

click to see more info on artifical lungs

By Anne Staylor, Medtech Insight 4/1/2011